PTC Therapeutics announced its fourth quarter and full-year 2024 financial results on February 27, 2025, reporting full-year 2024 total revenue of $807 million, which exceeded its guidance. For the fourth quarter of 2024, total revenues were $213.2 million, compared to $307.1 million in Q4 2023.
Net product revenue for Q4 2024 was $154.7 million, a slight decrease from $155.1 million in Q4 2023, while royalty revenue increased to $58.2 million from $51.0 million. The company reported a net loss attributable to common stockholders of $65.9 million, or $0.85 per share, for Q4 2024, and a full-year net loss of $363.3 million, or $4.73 per share.
As of December 31, 2024, cash, cash equivalents, and marketable securities totaled $1.14 billion, increasing to over $2.0 billion by January 2025 following the closing of the Novartis collaboration. PTC provided full-year 2025 total revenue guidance ranging from $650 million to $800 million, with non-GAAP R&D and SG&A expenses projected between $730 million and $760 million.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.